A new study identified that YTHDF1 deficiency in classical dendritic cells enhanced the cross-presentation of tumor antigens and the cross-priming of CD8+ T cells, and the therapeutic efficacy of the anti-PD-L1 drug was improved after blocking YTHDF1 (17). This evidence concerns the gene CD8A and neoplasm.